IMCR
BEARISH
$31.05
Live
Immunocore Holdings plc · NASDAQ
Target $63.86
(+105.7%)
$26.37
52W Range
$40.72
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 12, 2026
Market cap
$1.57B
P/E
N/A
ROE
-9.6%
Profit margin
-8.9%
Debt/Equity
1.15
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
IMCR exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 1/9, indicating poor financial health and operational deterioration. While the company maintains an impressive gross margin of 96.53% and positive revenue growth of 24.3%, these are offset by a catastrophic year-over-year EPS decline of 452.9% and a bearish insider sentiment. There is a stark disconnect between the aggressive analyst target price of $63.86 and the actual deterministic data, which suggests a high-risk profile characterized by consistent earnings misses and insider liquidation.
Key Strengths
Exceptional gross margins (96.53%) typical of high-value biotech products
Strong short-term liquidity with a current ratio of 4.04
Consistent positive revenue growth (24.3% YoY)
Operating margin is nearly at break-even (0.03%)
Significant upside potential according to analyst price targets ($63.86)
Key Risks
Critical financial health failure (Piotroski F-Score 1/9)
Severe earnings collapse with YoY EPS growth of -452.9%
Bearish insider activity with $4.35M in sales and zero buys
High valuation relative to book value (P/B 4.13) despite lack of profitability
Highly volatile earnings track record with frequent and large negative surprises
AI Fair Value Estimate
Based on comprehensive analysis
$32.5
+4.7% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
26
Weak
40
45
30
15
0
AI Verdict
High-Risk Speculative
Key drivers: Piotroski F-Score failure, Insider selling, EPS collapse, Strong liquidity
Confidence
90%
Value
40/100
Graham Number is N/A due to lack of positive earnings; valuation is purely speculative based on pipeline.
Positives
- P/S ratio of 3.94 is reasonable for growth biotech
Watchpoints
- Negative Forward P/E
- High Price/Book ratio (4.13)
Future
45/100
Growth in top-line revenue is not translating to bottom-line stability.
Positives
- Revenue growth remains positive at 24.3%
Watchpoints
- EPS growth is trending sharply downward
- Recent Q/Q EPS growth of -200%
Past
30/100
Historical earnings progression is erratic and unreliable.
Positives
- Occasional earnings beats in previous years
Watchpoints
- Average surprise of -30.94% over last 4 quarters
- Long-term 3Y price change of -38.5%
Health
15/100
Despite high liquidity, the deterministic health score is near the minimum.
Positives
- High current and quick ratios (>3.9)
Watchpoints
- Piotroski F-Score of 1/9 indicates extreme weakness
- Negative ROE and ROA
Dividend
0/100
Company is in a growth/burn phase; no capital returned to shareholders.
Positives
No standout positives identified.
Watchpoints
- No dividend payments
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$31.05
Analyst Target
$63.86
Upside/Downside
+105.7%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for IMCR and closest competitors.
Updated 2026-04-10
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
IMCR
Immunocore Holdings plc
Primary
|
-3.6% | -38.5% | +20.3% | -4.2% | -4.5% | +0.7% |
|
ANIP
ANI Pharmaceuticals, Inc.
Peer
|
+113.5% | +73.9% | +14.7% | -27.9% | -7.5% | -4.8% |
|
IOVA
Iovance Biotherapeutics, Inc.
Peer
|
-87.4% | -32.7% | +20.9% | +76.2% | -23.6% | +7.9% |
|
AGIO
Agios Pharmaceuticals, Inc.
Peer
|
-46.7% | +21.9% | -10.4% | -24.3% | +0.5% | +1.4% |
|
AXGN
Axogen, Inc.
Peer
|
+76.4% | +203.1% | +75.6% | +145.6% | +0.6% | +5.8% |
IMC
Immunocore Holdings plc
Primary
5Y
-3.6%
3Y
-38.5%
1Y
+20.3%
6M
-4.2%
1M
-4.5%
1W
+0.7%
ANI
ANI Pharmaceuticals, Inc.
Peer
5Y
+113.5%
3Y
+73.9%
1Y
+14.7%
6M
-27.9%
1M
-7.5%
1W
-4.8%
IOV
Iovance Biotherapeutics, Inc.
Peer
5Y
-87.4%
3Y
-32.7%
1Y
+20.9%
6M
+76.2%
1M
-23.6%
1W
+7.9%
AGI
Agios Pharmaceuticals, Inc.
Peer
5Y
-46.7%
3Y
+21.9%
1Y
-10.4%
6M
-24.3%
1M
+0.5%
1W
+1.4%
AXG
Axogen, Inc.
Peer
5Y
+76.4%
3Y
+203.1%
1Y
+75.6%
6M
+145.6%
1M
+0.6%
1W
+5.8%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-22.02
PEG Ratio
N/A
P/B Ratio
4.13
P/S Ratio
3.94
EV/Revenue
2.87
EV/EBITDA
-51.28
Market Cap
$1.57B
Profitability
Profit margins and return metrics
Profit Margin
-8.88%
Operating Margin
0.03%
Gross Margin
96.53%
ROE
-9.58%
ROA
-1.54%
Growth
Revenue and earnings growth rates
Revenue Growth
+24.3%
Earnings Growth
N/A
Q/Q Revenue Growth
+24.3%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
1.15
Moderate
Current Ratio
4.04
Strong
Quick Ratio
3.91
Excellent
Cash/Share
$17.05
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.1B
Gross Margin
97.4%
Op. Margin
-18.8%
Net Margin
-28.8%
Total Assets
$1.1B
Liabilities
$0.7B
Equity
$0.4B
Debt/Equity
1.80x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
109%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-06
$N/A
2026-02-25
$-0.6
-196.0% surprise
2025-11-06
$N/A
+100.0% surprise
2025-08-07
$-0.2
+3.1% surprise
Healthcare Sector Comparison
Comparing IMCR against 264 companies in the Healthcare sector
(20 bullish, 87 neutral, 157 bearish)
Return on Equity (ROE)
-9.58%
This Stock
vs
-46.09%
Sector Avg
-79.2%
(Below Avg)
Profit Margin
-8.88%
This Stock
vs
-19.58%
Sector Avg
-54.7%
(Weaker)
Debt to Equity
1.15
This Stock
vs
4.1
Sector Avg
-72.0%
(Less Debt)
Revenue Growth
24.3%
This Stock
vs
88.16%
Sector Avg
-72.4%
(Slower)
Current Ratio
4.04
This Stock
vs
3.58
Sector Avg
+12.9%
(Better)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
IMCR
Immunocore Holdings plc
|
BEARISH | $1.57B | - | -9.6% | -8.9% | $31.05 | |
|
ANIP
ANI Pharmaceuticals, Inc.
|
BEARISH | $1.58B | 21.23 | 16.2% | 8.9% | $70.49 | Compare |
|
IOVA
Iovance Biotherapeutics, Inc.
|
NEUTRAL | $1.52B | - | -55.5% | -148.4% | $3.7 | Compare |
|
AGIO
Agios Pharmaceuticals, Inc.
|
BEARISH | $1.63B | - | -30.2% | -% | $27.85 | Compare |
|
AXGN
Axogen, Inc.
|
NEUTRAL | $1.51B | - | -1.9% | -1.0% | $32.83 | Compare |
IMCR
Immunocore Holdings plc
BEARISH
Mkt Cap
$1.6B
P/E
-
ROE
-9.6%
Price
$31.05
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-18 | JALLAL BAHIJA | Chief Executive Officer | Sale | 11,474 | $371,184 |
| 2026-02-18 | GOLL JOHN R | Officer | Sale | 698 | $22,580 |
| 2026-02-18 | BERMAN DAVID M | Officer | Sale | 5,965 | $192,968 |
| 2026-02-18 | ST LEGER TINA AMBER | Officer | Sale | 1,000 | $32,350 |
| 2026-02-17 | JALLAL BAHIJA | Chief Executive Officer | Stock Award | 23,817 | - |
| 2026-02-17 | GOLL JOHN R | Officer | Stock Award | 1,351 | - |
| 2026-02-17 | BERMAN DAVID M | Officer | Stock Award | 11,824 | - |
| 2026-02-17 | ST LEGER TINA AMBER | Officer | Stock Award | 2,119 | - |
| 2025-12-04 | BERMAN DAVID M | Officer | Option Exercise | 31,341 | $1,260,378 |
| 2025-11-28 | BERMAN DAVID M | Officer | Sale | 74,925 | $3,005,825 |
| 2025-11-28 | BERMAN DAVID M | Officer | Option Exercise | 74,925 | $1,308,190 |
| 2025-11-25 | BERMAN DAVID M | Officer | Sale | 18,120 | $725,341 |
| 2025-11-25 | BERMAN DAVID M | Officer | Option Exercise | 18,120 | $316,375 |
JALLAL BAHIJA
Chief Executive Officer
2026-02-18
11,474 shares
·
$371,184
GOLL JOHN R
Officer
2026-02-18
698 shares
·
$22,580
BERMAN DAVID M
Officer
2026-02-18
5,965 shares
·
$192,968
ST LEGER TINA AMBER
Officer
2026-02-18
1,000 shares
·
$32,350
JALLAL BAHIJA
Chief Executive Officer
2026-02-17
23,817 shares
GOLL JOHN R
Officer
2026-02-17
1,351 shares
BERMAN DAVID M
Officer
2026-02-17
11,824 shares
ST LEGER TINA AMBER
Officer
2026-02-17
2,119 shares
BERMAN DAVID M
Officer
2025-12-04
31,341 shares
·
$1,260,378
BERMAN DAVID M
Officer
2025-11-28
74,925 shares
·
$3,005,825
BERMAN DAVID M
Officer
2025-11-28
74,925 shares
·
$1,308,190
BERMAN DAVID M
Officer
2025-11-25
18,120 shares
·
$725,341
BERMAN DAVID M
Officer
2025-11-25
18,120 shares
·
$316,375
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
13 analysts
Jefferies
2026-03-16
Buy
Hold
Needham
2026-02-26
Buy
Buy
HC Wainwright & Co.
2026-02-04
Buy
Buy
Morgan Stanley
2025-11-10
Equal-Weight
Equal-Weight
Wells Fargo
2025-10-31
Overweight
HC Wainwright & Co.
2025-10-22
Buy
Buy
Past News Coverage
Recent headlines mentioning IMCR from our newsroom.
Newest → oldest
No matching news yet.